Global Immune Checkpoint Inhibitors Market Growth 2025-2031
Description
The global Immune Checkpoint Inhibitors market size is predicted to grow from US$ 18880 million in 2025 to US$ 47640 million in 2031; it is expected to grow at a CAGR of 16.7% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
United States market for Immune Checkpoint Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Immune Checkpoint Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Immune Checkpoint Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Immune Checkpoint Inhibitors players cover Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Immune Checkpoint Inhibitors Industry Forecast” looks at past sales and reviews total world Immune Checkpoint Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Immune Checkpoint Inhibitors sales for 2025 through 2031. With Immune Checkpoint Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immune Checkpoint Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Immune Checkpoint Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immune Checkpoint Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Immune Checkpoint Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immune Checkpoint Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immune Checkpoint Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Immune Checkpoint Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
PD-1/PD-L1
CTLA-4
Segmentation by Application:
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bristol Myer Squibb
AstraZeneca
Merck
Roche / Genentech
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Key Questions Addressed in this Report
What is the 10-year outlook for the global Immune Checkpoint Inhibitors market?
What factors are driving Immune Checkpoint Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Immune Checkpoint Inhibitors market opportunities vary by end market size?
How does Immune Checkpoint Inhibitors break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
United States market for Immune Checkpoint Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Immune Checkpoint Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Immune Checkpoint Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Immune Checkpoint Inhibitors players cover Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Immune Checkpoint Inhibitors Industry Forecast” looks at past sales and reviews total world Immune Checkpoint Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Immune Checkpoint Inhibitors sales for 2025 through 2031. With Immune Checkpoint Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immune Checkpoint Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Immune Checkpoint Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immune Checkpoint Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Immune Checkpoint Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immune Checkpoint Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immune Checkpoint Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Immune Checkpoint Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
PD-1/PD-L1
CTLA-4
Segmentation by Application:
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bristol Myer Squibb
AstraZeneca
Merck
Roche / Genentech
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Key Questions Addressed in this Report
What is the 10-year outlook for the global Immune Checkpoint Inhibitors market?
What factors are driving Immune Checkpoint Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Immune Checkpoint Inhibitors market opportunities vary by end market size?
How does Immune Checkpoint Inhibitors break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
96 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Immune Checkpoint Inhibitors by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Immune Checkpoint Inhibitors by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
